Palbociclib and ribociclib are both approved for the treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer patients in combination with endocrine therapy. Here, ERBB2 is linked to breast carcinoma.